Tropic Raises $105M to Scale Gene‑Edited Bananas

Tropic Biosciences, an agri‑biotech startup based in Norwich, has secured $105 million in a Series C round to scale production of its gene‑edited banana varieties. The company launched the first new commercial banana types in more than 75 years in 2025, designed to withstand Panama disease Tropical Race 4 (TR4), a soil‑borne fungal pathogen threatening global banana crops.

Bananas are a staple for hundreds of millions worldwide and a major export for several countries. TR4 spreads in soil and water, is extremely difficult to eradicate, and has devastated plantations across Asia, Africa and Latin America. Tropic’s gene‑edited plants aim to provide growers with resistant material that keeps yields stable without reliance on intensive chemical controls.

The fresh capital will be used to expand upstream and downstream production capacity, strengthen regulatory and supply chain operations, and accelerate partnerships with growers and distributors worldwide. Tropic needs to move quickly: demand for resistant planting material is already high, and commercial uptake will depend on steady, certified supply to replace vulnerable varieties in the field.

Investors say the round reflects both the urgency of the crisis and the commercial potential of resilient banana varieties. For farmers, the ability to source resistant plants at scale could mean the difference between sustained livelihoods and severe crop losses. For consumers, it could preserve the availability and price stability of a globally popular fruit.

While gene editing still faces regulatory and public acceptance hurdles in some markets, Tropic’s progress so far highlights how targeted biotech can tackle plant diseases that traditional breeding hasn’t solved. If the company can deliver supply reliably, this could become a blueprint for rapid response to other crop threats.